Amphetamine salts (Adderall, Adderall XR) are Schedule II CNS stimulants composed of mixed amphetamine salts — approximately 75% dextroamphetamine (d-amphetamine) and 25% levoamphetamine (l-amphetamine) — used to treat ADHD and narcolepsy. They work by causing massive release of dopamine and norepinephrine from nerve terminals while also blocking their reuptake, producing sustained catecholamine stimulation. Cardiovascular effects (increased heart rate and blood pressure), appetite suppression, and insomnia are common. High abuse potential exists, particularly outside of therapeutic use.
Amphetamine Salts
Uses & FDA Indications
Amphetamine salts are FDA-approved for attention-deficit/hyperactivity disorder (ADHD) in children aged 3 and older (IR) or 6 and older (XR), as well as adults. They are also approved for narcolepsy. Adderall is one of the most recognized ADHD medications in the United States and among the most prescribed stimulants.
In ADHD, stimulants are considered first-line pharmacotherapy — the evidence base for their efficacy in reducing inattention, hyperactivity, and impulsivity is among the strongest of any psychiatric medication class. In narcolepsy, amphetamines promote wakefulness and reduce cataplexy symptoms.
Non-medical use (misuse) for cognitive enhancement, weight loss, or recreational purposes is common, particularly among college students. This misuse profile is part of why amphetamine salts retain Schedule II classification despite established therapeutic use.
BLACK BOX WARNING: Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death and serious cardiovascular adverse events. Adderall should be prescribed or dispensed sparingly. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence during therapy.
How It Works
Amphetamines are indirect sympathomimetics that work through multiple complementary mechanisms. The primary mechanism is reversal of monoamine transporters: amphetamine enters presynaptic neurons via dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), where it causes reverse transport — pumping dopamine, norepinephrine, and serotonin out of the neuron into the synapse at rates far exceeding normal neuronal firing.
Additionally, amphetamine inhibits reuptake of these monoamines, blocks monoamine oxidase (MAO) at high concentrations, and causes release from intracellular vesicles via VMAT2 disruption. The net result is a massive, sustained surge of dopamine and norepinephrine in critical brain circuits — the prefrontal cortex (attention, executive function), the mesolimbic system (motivation, reward), and peripheral sympathetic nervous system (cardiovascular effects).
The therapeutic mechanism in ADHD is not fully understood, but the prevailing model suggests that ADHD involves dysregulation of catecholamine signaling in the prefrontal cortex — affecting working memory and executive function. Stimulants normalize this signaling at therapeutic doses in people with ADHD. The same dopamine surge that produces therapeutic focus also underlies the abuse potential: misuse at higher doses or via non-oral routes (insufflation, IV) produces intense euphoria through rapid dopamine release in the nucleus accumbens.
Side Effects
Common
- Appetite suppression and weight loss — significant and often persistent; concern for growth in children with long-term use; periodic "drug holidays" are sometimes recommended
- Insomnia — particularly if taken too late in the day; long half-life contributes; a key reason for dosing in morning hours
- Increased heart rate and blood pressure — dose-dependent; typically modest at therapeutic doses but clinically important in cardiovascular risk patients
- Dry mouth
- Headache
- Irritability and emotional lability — particularly as the dose wears off ("rebound effect")
- Anxiety and nervousness
Serious
- Cardiovascular events — sudden cardiac death has been reported in patients with structural cardiac abnormalities; serious arrhythmias; hypertensive crisis at high doses
- Psychiatric effects — new or worsened psychosis, mania, aggression, paranoia — particularly in patients with pre-existing psychiatric conditions or at high doses
- Stimulant use disorder — physical and psychological dependence; withdrawal causes profound fatigue, hypersomnia, depression, and dysphoria
- Raynaud's phenomenon — peripheral vasospasm causing cold, pale, or blue extremities
- Serotonin syndrome — when combined with serotonergic agents, especially MAOIs
- Growth suppression in children — chronic stimulant use may reduce expected height gain; growth should be monitored
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| MAO Inhibitors (phenelzine, selegiline, tranylcypromine, linezolid) | Combination with amphetamines can cause life-threatening hypertensive crisis and serotonin syndrome. Amphetamine-induced monoamine release is massively amplified when MAO breakdown is inhibited. | Critically High — absolute contraindication; 14-day washout required |
| Antihypertensives | Amphetamines raise blood pressure and heart rate, antagonizing the effect of antihypertensive medications. Patients on blood pressure treatment may require medication adjustments. | Moderate — monitor blood pressure; may need antihypertensive dose increase |
| Serotonergic Drugs (SSRIs, SNRIs, tramadol, triptans) | Risk of serotonin syndrome, especially with MAOIs. Amphetamine releases serotonin in addition to dopamine and norepinephrine. | Moderate — monitor for serotonin toxicity symptoms (hyperthermia, agitation, clonus, hyperreflexia) |
| Acidifying agents (ascorbic acid/Vitamin C, ammonium chloride, fruit juice) | Urinary and GI acidification increases ionization of amphetamine, reducing absorption and increasing renal excretion — lowering plasma levels and shortening duration. | Moderate — avoid large amounts of acidic foods/drinks around dosing time |
| Alkalinizing agents (sodium bicarbonate, some antacids) | Increase amphetamine absorption and reduce renal excretion, potentially increasing blood levels and duration of effect. | Moderate — separate administration; monitor for enhanced effects |
| Lithium | Lithium may blunt the stimulant and euphoric effects of amphetamines through multiple mechanisms including dopamine modulation. | Low-Moderate — may reduce therapeutic effect; monitor ADHD symptom control |
Warnings & Contraindications
Contraindications
- Advanced arteriosclerosis
- Symptomatic cardiovascular disease
- Moderate to severe hypertension
- Hyperthyroidism
- Known hypersensitivity or idiosyncrasy to sympathomimetic amines
- History of drug abuse
- During or within 14 days of MAOI treatment
- Agitated states
- Glaucoma
Cardiovascular Screening
Before initiating amphetamine therapy, a thorough personal and family cardiac history should be taken. Blood pressure and pulse should be documented at baseline and monitored at each follow-up visit. Patients who develop exertional chest pain, unexplained syncope, or significant cardiac arrhythmia during treatment should be promptly evaluated. Structural cardiac abnormalities that increase sudden cardiac death risk are a contraindication to stimulant therapy.
Psychiatric Monitoring
Amphetamines can exacerbate or unmask psychiatric conditions including psychosis, bipolar disorder, and mania. Prior to initiating therapy, patients should be screened for personal or family history of psychosis or bipolar disorder. New or worsened psychiatric symptoms — particularly hallucinations, delusional thinking, or manic episodes — should prompt discontinuation and psychiatric evaluation. In patients with ADHD and comorbid psychiatric conditions, stimulant initiation requires particularly careful monitoring.
Check for amphetamine interactions with MAOIs, antidepressants, and other medications.
Check Drug Interactions →Frequently Asked Questions
What is the difference between Adderall and Adderall XR?
Adderall (immediate-release) and Adderall XR (extended-release) both contain the same mixed amphetamine salts (75% dextroamphetamine, 25% levoamphetamine salts) but differ in their release mechanism and duration. Immediate-release Adderall has an onset of 30–60 minutes and duration of approximately 4–6 hours, typically requiring multiple daily doses. Adderall XR uses a bead technology — half the beads release immediately, half release 4 hours later — providing 10–12 hours of effect with a single morning dose. XR is generally preferred for school-age children and adults to avoid mid-day dosing and reduce missed doses.
Is Adderall safe for people with heart conditions?
Amphetamine salts cause dose-dependent increases in heart rate and blood pressure, which can be problematic for patients with pre-existing cardiovascular disease. The FDA and prescribing guidelines generally recommend against stimulant use in patients with serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm disorders, coronary artery disease, or other serious cardiac conditions. Before initiating stimulant therapy, patients should have a thorough cardiovascular history taken and blood pressure and pulse recorded. Patients with controlled, mild cardiovascular conditions may still be candidates for stimulants under careful monitoring, but the risk-benefit assessment should be made by a physician familiar with the patient's cardiac status.
Does Adderall cause long-term brain changes?
Research on long-term neurological effects of therapeutic amphetamine use in ADHD patients is ongoing and complex. Studies suggest that in people with ADHD, stimulant treatment may normalize certain patterns of dopaminergic activity rather than causing pathological changes. However, amphetamine at high doses or in individuals without ADHD causes different neurobiological effects — including alterations in dopamine receptor density and downregulation of dopamine transporters. The distinction between therapeutic and non-medical use is pharmacologically important. Patients taking amphetamines as prescribed for ADHD at therapeutic doses have a different risk profile than individuals misusing stimulants at higher doses or via non-oral routes.